With commercial insurance: ACTEMRA Co-pay Program — as little as $0, up to $15,000 per calendar year. With Medicare: the Actemra card can’t be used. All 4 foundation funds we checked are closed as of October 12, 2026.
See what this patient owes after assistance →
6 assistance programs for Actemra patients · 2 open today
Manufacturer savings, charitable foundations, and patient assistance programs.
Select the patient's insurance and diagnosis to see which programs may apply.
Current status · Award amounts · Eligibility · Direct application links October 12, 2026
Which form this covers: IV Actemra is clinic-billed (medical benefit). SC Actemra is a pharmacy product. The card pays for the drug only, not the infusion visit.
Checked September 28, 2026 · Source 1 ↗ · Source 2 ↗
Checked September 28, 2026 · Source ↗
Actemra’s card can’t be used with Medicare. These funds may help. They open and close with donations, so call before telling a Actemra patient no.
Checked September 28, 2026 · Source 1 ↗ · Source 2 ↗
Actemra · Rheumatoid arthritis · Commercial insurance
Eligible patients may pay $0
Example · Actemra · 640 mg · 640 units · commercial plan · deductible met · 20% coinsurance · allowed amounts at the Medicare reference rate
| Without assistance | With ACTEMRA Co-pay Program (Genentech; RACopay.com) | |
|---|---|---|
| Drug responsibility | $681.60 | $0.00 |
| Administration (96365) | $13.43 | $13.43 |
| Patient owes | $695.03 | $13.43 |
Estimated patient savings: $681.60
CareCost calculates the drug and administration lines using the patient’s payer rate and benefits; this example uses the Medicare rate as a reference.
Also available if this patient’s coverage falls short
Free Genentech Patient Foundation (Free Drug) for eligible patients
Change the diagnosis to see only the programs that apply to your patient.
Actemra shares its class with Orencia (IV) (J0129, Bristol Myers Squibb), Remicade (J1745, Janssen), Simponi Aria (J1602, Janssen), billed under their own codes with their own manufacturer programs. The programs above apply to Actemra only. If the payer requires Orencia, Remicade or Simponi Aria instead of Actemra, use that maker’s program below.
Each Orencia, Remicade or Simponi Aria card shows the date we last checked that program. Copay cards also say whether they pay the infusion or injection fee.
ORENCIA On Call Co-pay Assistance (SC and IV)
BMS Patient Assistance Foundation (Orencia)
J&J withMe Savings Program (Remicade/Infliximab)
Johnson & Johnson Patient Assistance Program (Remicade)
Janssen CarePath Savings Program (Simponi Aria)
Johnson & Johnson Patient Assistance Foundation (Simponi Aria)
| Task | ✓ |
|---|---|
| Find programs for the diagnosis | ✓ |
| See whether each program is open | ✓ |
| See maximum award | ✓ |
| Review key eligibility requirements | ✓ |
| Open the official application | ✓ |
| Calculate cost before assistance | ✓ |
| Apply the program benefit | ✓ |
| Calculate what the patient still owes | ✓ |
Commercial insurance — the ACTEMRA Co-pay Program Program brings the patient's cost on the drug charge to $5 per infusion, up to $15,000 per calendar year. The benefit applies to the Actemra drug line only; it does not cover the 96365 administration line or other office-visit fees, and it excludes Medicare, Medicaid and other government insurance. View current program ↑
Medicare — the ACTEMRA Co-pay Program Program excludes Medicare, Medicaid and other government insurance, and the Genentech Patient Foundation's free-drug program is limited to patients who are uninsured or in a coverage gap, so an insured Medicare patient does not qualify for either. Two HealthWell Foundation funds could otherwise help: AutoImmune Medicare Access, up to $2,800 a year, and Giant Cell Arteritis or Temporal Arteritis Medicare Access, up to $4,500 a year; check each fund's current status on the funds list. A Medigap plan can pick up the Part B coinsurance instead; see the cost page for the Plan K and Plan L figures.
HealthWell's ANCA-associated vasculitis fund (up to $6,000 a year) is for a condition Actemra is not FDA-approved for, so it does not apply here. The funds that match an Actemra indication are HealthWell's AutoImmune Medicare Access, HealthWell's Giant Cell Arteritis or Temporal Arteritis Medicare Access, and TotalAssist's Rheumatoid Arthritis fund; check each fund's current status on the funds list.
How the lines work — an 8 mg/kg dose for an 80 kg patient with rheumatoid arthritis is 640 mg, billed as the drug line, J3262 × 640 units, drawn from one 400 mg vial and three 80 mg vials with nothing discarded. The infusion itself is a separate line, 96365, for the 60-minute drip. Each line carries its own patient share under commercial coinsurance, and neither Genentech program pays the 96365 line.
Yes. The ACTEMRA Co-pay Program Program brings the drug cost to $5 per infusion for commercially insured patients, up to $15,000 per calendar year. Apply on Genentech ↗ Calculate cost with the program →
No. The program covers the Actemra drug charge only. The administration line (96365) and any office-visit fee are the patient's responsibility regardless of enrollment. View current program ↑
Not from Genentech directly: the Actemra co-pay program excludes Medicare, Medicaid and other government insurance, and the Patient Foundation’s free-drug program takes uninsured patients, patients whose plan does not cover Actemra, and insured patients with high out-of-pocket costs. Three funds could apply: HealthWell's AutoImmune Medicare Access, HealthWell's Giant Cell Arteritis or Temporal Arteritis Medicare Access, and TotalAssist's Rheumatoid Arthritis fund; check each fund's current status on the funds list. A Medigap plan can cover the Part B coinsurance instead; see the cost page. Check current Medicare options ↑
Patients who are uninsured or have a coverage gap, with income with household income under $150,000, can apply through Genentech; approved patients have the drug shipped directly to the provider, with no insurance billed for the drug charge. Apply on Genentech ↗
HealthWell's ANCA-associated vasculitis fund (up to $6,000 a year) is for a condition Actemra is not FDA-approved for, so it does not apply. The funds that match an Actemra indication are HealthWell's AutoImmune Medicare Access ($2,800), HealthWell's Giant Cell Arteritis or Temporal Arteritis Medicare Access ($4,500), and TotalAssist's Rheumatoid Arthritis fund ($4,000); check each fund's current status on the funds list. TotalAssist also runs Ankylosing Spondylitis and Psoriatic Arthritis funds, both closed and neither an Actemra indication. Check today's status ↑
A denial does not change the Actemra assistance programs available; a commercially insured patient can still use ACTEMRA Co-pay Program once coverage is resolved, and an eligible uninsured patient can apply to the Patient Foundation regardless of the payer decision. Review the plan's prior authorization requirements on the coverage page.
Data current: programs verified Oct 12, 2026
ACTEMRA Co-pay Program Program and Genentech Patient Foundation (Free Drug) (Genentech Patient Support) · ORENCIA On Call Copay Program and BMS Patient Assistance Foundation (Orencia, Bristol Myers Squibb), J&J withMe Savings Program and Johnson & Johnson Patient Assistance Program (Remicade, Janssen), Janssen CarePath Savings Program and Johnson & Johnson Patient Assistance Foundation (Simponi Aria, Janssen), shown above for the other products in this drug's class. Every program links directly to its official source or application page.
Last program check: .
Reviewed September 21, 2026 by Erin Rose, CareCost Estimate founder. Methodology →
CareCost